Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Current Liabilities (2016 - 2026)

Aytu Biopharma has reported Total Current Liabilities over the past 15 years, most recently at $65.6 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 2.37% to $65.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.6 million through Dec 2025, up 2.37% year-over-year, with the annual reading at $63.1 million for FY2025, 1.34% up from the prior year.
  • Total Current Liabilities was $65.6 million for Q4 2025 at Aytu Biopharma, down from $66.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $109.4 million in Q2 2021 and troughed at $61.3 million in Q3 2024.
  • The 5-year median for Total Current Liabilities is $67.1 million (2022), against an average of $74.4 million.
  • Year-over-year, Total Current Liabilities surged 355.67% in 2021 and then crashed 41.12% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $100.6 million in 2021, then tumbled by 33.23% to $67.1 million in 2022, then dropped by 4.41% to $64.2 million in 2023, then fell by 0.22% to $64.0 million in 2024, then increased by 2.37% to $65.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Current Liabilities are $65.6 million (Q4 2025), $66.0 million (Q3 2025), and $63.1 million (Q2 2025).